Market Size of Alpha-glucosidase Inhibitors Industry
| Study Period | 2017- 2028 |
| Market Size (2023) | USD 4.66 Billion |
| Market Size (2028) | USD 5.19 Billion |
| CAGR (2023 - 2028) | 2.17 % |
| Fastest Growing Market | Middle East and Africa |
| Largest Market | Asia Pacific |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Alpha-glucosidase Inhibitors Market Analysis
The Alpha-glucosidase Inhibitors Market size is estimated at USD 4.66 billion in 2023, and is expected to reach USD 5.19 billion by 2028, growing at a CAGR of 2.17% during the forecast period (2023-2028).
The market is estimated to reach a value of about USD 5.1 billion by 2027.
The COVID-19 pandemic positively impacted the Alpha-glucosidase Inhibitors market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.
Alpha-glucosidase inhibitors are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates. Carbohydrates are converted into monosaccharides by alpha-glucosidase enzymes present in cells lining the intestine, enabling monosaccharides to be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of dietary carbohydrates on blood sugar. Alpha-glucosidase inhibitors are used to establish greater glycemic control over hyperglycemia in diabetes mellitus type 2, they may be used as monotherapy in conjunction with an appropriate diabetic diet and exercise, or they may be used in conjunction with other anti-diabetic drugs. Therefore, they have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.
In May 2021, the World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes. It recommends action in areas including increasing access to medicines and health products for the treatment of diabetes and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to the transparency of markets for diabetes medicines and health products.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
